News Hub

Real-time financial, economic, and global news with market-focused context and analysis.

Coverage spans equities, macroeconomic data, commodities, currencies, technology, politics, and global events—paired with analysis that highlights why each development matters for traders and investors. From breaking headlines to hourly market snapshots and in-depth articles, the News Hub is designed to help you stay informed, oriented, and ahead of market-moving events.

  • Meridian Holdings' Meridianbet named official sponsor of UFC Fight Night Belgrade, marking the UFC's first Serbia event and boosting Meridianbet's global betting visibility.
  • Waste Management recommended as a tactical buy after pullback, citing a $3B buyback and 23-year dividend-growth streak.
  • Chevron pitched as a buy on supply-constrained oil dynamics, with a $205 45-day target and a $176 protective stop.
  • AMD viewed as a measured long ahead of its Aug 4 earnings, advising size-managed exposure due to binary risk.
  • Autodesk recommended as an AI-era value buy after a strategic bolt-on M&A and signs management is leaning into AI.
  • Analysts' buy-the-dip calls across energy, semiconductors, and software imply a short-term risk-on tilt in markets.

Latest Articles

Shattuck Labs Announces Phase 1 Results for SL-325

Shattuck Labs Announces Phase 1 Results for SL-325

Shattuck Labs announced positive Phase 1 trial results for SL-325, its lead monoclonal antibody targeting the DR3 receptor involved in inflammatory and immune-mediated diseases. The trial demonstrated favorable safety, durable receptor occupancy with complete TL1A blockade lasting over three months, and a low immunogenicity rate of 3.7%. The compan…

Lyell Immunopharma Provides Update on Safety Profile of LYL273 in Relapsed or Refractory Metastatic Colorectal Cancer and Amends Phase 1 Trial to Phase 1/2 Expansion

Lyell Immunopharma Provides Update on Safety Profile of LYL273 in Relapsed or Refractory Metastatic Colorectal Cancer and Amends Phase 1 Trial to Phase 1/2 Expansion

Lyell Immunopharma announced favorable safety data from its Phase 1 clinical trial of LYL273 in relapsed or refractory metastatic colorectal cancer, noting a significant reduction in severe gastrointestinal side effects through prophylaxis. The trial has been amended to a seamless Phase 1/2 design with expanded patient cohorts, including second-lin…

Lixiang Education Regains Compliance with Nasdaq Minimum Market Value of Publicly Held Shares Requirement

Lixiang Education Regains Compliance with Nasdaq Minimum Market Value of Publicly Held Shares Requirement

Lixiang Education Holding Co., Ltd., a private education services provider based in China, announced it has regained compliance with Nasdaq's minimum market value of publicly held shares requirement after its market value exceeded $5 million for ten consecutive business days ending June 4, 2026. This resolves a previous non-compliance issue noted i…

Pre-Feasibility Study for Grey Fox at Fox Complex — High Returns, Manageable Capital, Mine Life Extended to 2041

Pre-Feasibility Study for Grey Fox at Fox Complex — High Returns, Manageable Capital, Mine Life Extended to 2041

McEwen Inc. announced the results of the Pre-Feasibility Study (PFS) for its Grey Fox Project near Timmins, Ontario, extending the Fox Complex mine life to 2041 and projecting increased gold production. With an estimated initial capital expenditure of $181 million and robust economics assuming gold prices over $4,000/oz, the project is expected to …

Enigmatig Limited Issues Statement on Recent Share Trading Activity

Enigmatig Limited Issues Statement on Recent Share Trading Activity

Enigmatig Limited issued a statement responding to recent unusual trading activity in its shares on June 4 and 5, 2026. The company confirmed it is unaware of any new material information or developments that have not been previously disclosed. It reiterated its commitment to compliance with disclosure obligations under federal securities laws and …

Wolfe Research Sees Technology Driving a Narrow U.S. Market Rally

Wolfe Research Sees Technology Driving a Narrow U.S. Market Rally

Wolfe Research says last week’s end to the S&P 500’s winning streak reflected stronger-than-expected employment data and geopolitical tensions, but the firm does not view the pullback as a reversal. The research house favors technology and semiconductor stocks, expects sentiment to recover if upcoming inflation readings are benign, and warns that m…

American Battery Technology Company Wins Appeal and Has US Department of Energy Grant Reinstated for $115 million Project for Commercial Scale Critical Mineral Lithium Refinery

American Battery Technology Company Wins Appeal and Has US Department of Energy Grant Reinstated for $115 million Project for Commercial Scale Critical Mineral Lithium Refinery

American Battery Technology Company (NASDAQ: ABAT) successfully won an appeal to reinstate a $115 million U.S. Department of Energy grant supporting its Tonopah Flats Lithium Project, a major commercial-scale critical mineral lithium refinery in Nevada. The reinstatement follows a rigorous review confirming the project’s achievement of all technica…

Duluth Holdings Inc. Announces First Quarter 2026 Financial Results

Duluth Holdings Inc. Announces First Quarter 2026 Financial Results

Duluth Holdings Inc. announced its first quarter fiscal 2026 financial results, showing a net loss improvement to $10 million from $15.3 million in the prior year, and an increase in adjusted EBITDA by $6.4 million to $2.6 million. The company achieved a gross margin expansion of 540 basis points to 57.4%, reduced inventory significantly by 24.8%, …

enGene Therapeutics: Oversold Biotech — A Risk-Adjusted Bounce Trade

enGene Therapeutics: Oversold Biotech — A Risk-Adjusted Bounce Trade

enGene (ENGN) has plunged from a $12.25 peak to under $2. The balance sheet is thin and the company burns cash, but the stock is deeply oversold (RSI 28.5) and trading at a sub-0.4 P/B with an enterprise value below $100M. For traders willing to accept biotech binary risk, a disciplined long with a tight stop and a clear time horizon can offer asym…

UBS Elevates Porsche to Buy, Sees Turnaround Gaining Traction

UBS Elevates Porsche to Buy, Sees Turnaround Gaining Traction

UBS has upgraded Porsche AG to Buy and increased its price target to €60 from €40, citing three core recovery drivers: a more balanced product mix to reduce EV concentration, improved execution under new management, and a leaner cost base sized for annual volumes of about 250,000-280,000 vehicles. The bank expects operating margins to rise from rou…

Ithaca Energy Jumps After Jefferies Lifts Target, M&A Talk Adds Fuel

Ithaca Energy Jumps After Jefferies Lifts Target, M&A Talk Adds Fuel

Ithaca Energy shares climbed 6.1% to 253.4p after Jefferies raised its price target to 350p from 210p and maintained a Buy rating. The broker described Ithaca as "a transformed investment case" following its 2024 combination with Eni UK and cited media reports of discussions with BP on a possible North Sea transaction. The move comes after a recent…

Jefferies Lifts Base Metals Price Outlook Citing Stronger Demand Signals

Jefferies Lifts Base Metals Price Outlook Citing Stronger Demand Signals

Jefferies has revised up its price forecasts for base metals, projecting a higher copper peak and raising aluminum expectations. The bank attributes the change to a market transition from supply-led to demand-led conditions, supported by spending on data centers and power infrastructure in the United States, while noting persistent supply constrain…

Ithaca Energy Shares Rally After Jefferies Boosts Price Target to 350p

Ithaca Energy Shares Rally After Jefferies Boosts Price Target to 350p

Ithaca Energy Plc jumped more than 6% on Monday after Jefferies raised its price target to 350p from 210p and kept a "buy" rating, citing the company’s transformation since its business combination with Eni UK in April 2024. Jefferies’ new target reflects a blend of net asset value and an EV/EBITDA multiple applied to 2026-27 estimates, and comes a…

Aker BP's Johan Sverdrup Share Inches Up to 31.7% After Redetermination

Aker BP's Johan Sverdrup Share Inches Up to 31.7% After Redetermination

Aker BP's stake in the Johan Sverdrup North Sea oil field has been raised to 31.7% from 31.6% following a redetermination process that began in January 2025. The company will receive an additional 2.2 million barrels of oil equivalent from the field over the next two years and will make a payment of roughly 300 million Norwegian crowns (about $31.7…